Biogen Inc (BIIB) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Total Assets Chart for Biogen Inc
Biogen Inc (BIIB) total assets for FY2025 were USD 29.4B, a 5.0% change from FY2024. Biogen Inc's total assets grew from USD 85.8M in 1985 to USD 29.4B in 2025 (34211.8% over 40 years). Total assets compound annual growth rate: 5-year CAGR of 3.6%, 10-year CAGR of 4.2%, 20-year CAGR of 6.5%.
Total Assets (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $30.48B
- Implied Share Price
- $206.28
- Enterprise Value
- $37.87B
- Revenue (TTM)
- $10.03B
- EBITDA
- $3.36B
- Profit Margin
- 8.32%
- Trailing P/E
- 36.77
- Forward P/E
- 17.09
- Price/Book (MRQ)
- 1.63
- Price/Sales (TTM)
- 3.04
- EV/EBITDA
- 17.70
- EV/Revenue
- 3.78
- Dividend Yield
- —
- Book Value
- $127.61
- Free Cash Flow (FY2025)
- $2.05B
- Free Cash Flow Yield
- 6.73%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.